Gregg Siegal obtained his Ph.D. on studies of eukaryotic DNA replication at the University of Rochester in the USA under the supervision of Professor Robert Bambara. Subsequently he post-Doc’ed in the laboratories of Professor Kurt Wüthrich at the ETH in Switzerland and Professor Paul Driscoll at the Ludwig Institute of Cancer Research in the UK. It was during his post-Doctoral work that Dr. Siegal was exposed to NMR as a tool for both structural biology and drug discovery. He moved to Leiden University in 1997 where he received a Dutch Royal Society Fellowship to form his own research group. His research focused on the development and application of innovative drug discovery technologies. In 2004 he spun out the company ZoBio to commercialize the TINS ligand screening technology and eventually left Leiden University to serve as the Chief Executive Officer. At the end of 2023 ZoBio was acquired and merged with Oncodesign Services to provide Gene-to-IND services. In 2018 he was appointed as an extraordinary Professor in the Division of Medicinal Chemistry at the Free University, Amsterdam.